Recipharm completes a directed issue of 2.25 million Class B shares, raising proceeds of approximately SEK 276 million

NOT FOR DISTRIBUTION OR RELEASED, DIRECTLY OR INDIECTLY, IN OR INTO THE UNITED
STATES, CANADA, AUSTRALIA, JAPAN OR ANY OTHER JURISDICTION, IN WHICH THE
DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL.
Recipharm AB (publ) (“Recipharm”) has, based on the authorization granted by
Recipharm’s Annual General Meeting on 7 May, 2015, resolved to carry out a
direct share issue of 2,250,000 Class B shares at subscription price of SEK
122.50 per share (the “Issue”). The subscription price represents a discount of
approximately 0.2 per cent compared to one week volume weighted average price
prior to the Board of Directors’ resolution [1] , and a discount of
approximately 0.8 per cent compared to the closing price on 25 January, 2016
[2]. Subscribers in the Issue are a few well known institutional investors. The
reasons for deviation from the shareholders’ preferential rights is to diversify
the shareholder base and at the same time raise capital in a time efficient
manner to partly finance acquisition, previously announced during the fourth
quarter 2015.

Through the Issue, Recipharm will receive proceeds amounting to approximately
SEK 275.6 million before transaction costs. The Issue entails a dilution of
approximately 4.7 per cent of the capital in relation to the number of shares in
Recipharm through an increase in the number of outstanding shares to 48,075,256
(divided into 12,685,716 shares of Class A and 35,389,540 shares of Class B).

Carnegie Investment Bank AB (publ) has acted as financial advisor in connection
with the transaction.

For further information please visit www.recipharm.com or contact:
Thomas Eldered, CEO, thomas.eldered@recipharm.com, telephone: +46 8 602 52 10
Björn Westberg, CFO, bjorn.westberg@recipharm.com, telephone: +46 8 602 46 20

This information is published in accordance with the Swedish Securities Market
Act, the Swedish Financial Instruments Trading Act and/or the regulations of
Nasdaq Stockholm. This information was submitted for publication on 26 January,
2016, at 08.00 am CET.

Important information
The release, announcement or distribution of this press release may in certain
jurisdictions be restricted. The recipient of this press release is responsible
for using the information in this press release in accordance with the
applicable law in each jurisdiction. This press release does not constitute an
offer, or a solicitation of any offer, to buy or subscribe for any securities in
Recipharm AB in any jurisdiction, neither of Recipharm AB or any other party.
About Recipharm
Recipharm is a leading CDMO company (Contract Development and Manufacturing
Organisation) in the pharmaceutical industry based in Sweden employing some
2,500 employees. Recipharm offers manufacturing services of pharmaceuticals in
various dosage forms, production of clinical trial material including API and
pharmaceutical product development. Recipharm manufactures several hundred
different products to customers ranging from Big Pharma through to smaller
research- and development companies. Recipharm’s turnover is approximately SEK
3.4 billion and the Company operates development and manufacturing facilities in
Sweden, France, the UK, Germany, Spain, Italy and Portugal and is headquartered
in Jordbro, Sweden. The Recipharm B-share (RECI B) is listed on Nasdaq
Stockholm.
For more information on Recipharm and our services, please visit
www.recipharm.com.

[1] SEK 122.72 one week volume weighted average closing price prior to Board of
Directors resolution.

[2] SEK 123.50 closing price 25 January, 2016.
Recipharm AB (publ)
Corporate identity number 556498-8425
Address Lagervägen 7, SE-136 50 Jordbro, Sweden, Telephone 46 8 602 52
00, Fax 46 8 81 87 03
www.recipharm.com